share_log

RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target

Benzinga ·  Aug 15 10:35  · Ratings

RBC Capital analyst Brian Abrahams reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $181 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment